Revolution Medicines Inc (RVMD) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Cash and Investments: $2.03 billion at the end of Q4 2025. R&D Expenses: $294.9 million for Q4 2025, up from $188.1 million in Q4 2024. G&A Expenses: $66.7 million for Q4 2025, up from $28.2 million in Q4 2024. Net Loss: $364.9 million for Q4 2025, compared to $194.6 million in Q4 2024. Stock-Based Compensation Expense: $33.7 million in Q4 2025. Non-Cash Warrant Expense: $12.6 million related to a mark-to-market change in Q4 2025. Non-Cash Interest Expense: $11.9 million related to the royalty pharma arrangement in Q4 2025. 2026 GAAP Operating Expenses Guidance: Expected between $1.6 and $1.7 billion. 2026 Stock-Based Compensation Expense Guidance: Estimated between $180 and $200 million. Warning! GuruFocus has detected 3 Warning Sign with RVMD. Is RVMD fairly valued? Test your thesis with our free DCF calculator. Release Date: February 25, 2026 For the complete transcript of the earnings call, please refer to the ful
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- This One Data Readout Could Make Or Break Revolution Medicines [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) is now covered by UBS Group AG. They set a "buy" rating and a $145.00 price target on the stock.MarketBeat
- Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here's Why [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 3/6/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- RVMD's page on the SEC website